Renal Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: Involvement of Chronic Graft-Versus-Host Disease

Akiko Mii1, Akira Shimizu2, Tomohiro Kaneko1, Kazutaka Nakayama3, Hiroki Yamaguchi3 and Shuichi Tsuruoka1
1Department of Nephrology, Nippon Medical School, Tokyo, Japan; 2Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan; and 3Department of Hematology, Nippon Medical School, Tokyo, Japan

Correspondence: Akiko Mii, Department of Nephrology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan. E-mail: m-akiko@nms.ac.jp

Kidney Int Rep (2018) 3, 743–747; https://doi.org/10.1016/j.ekir.2017.12.013
© 2018 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

INTRODUCTION

Hematopoietic stem cell transplantation (HSCT) is a widely accepted treatment for malignant and nonmalignant disorders. Recent advances in transplantation techniques have increased the rate of long-term survival. However, kidney complications after HSCT are an important challenge.1,2 Recent studies have shown that the prevalence of chronic kidney disease (CKD) is approximately 20% in HSCT recipients.2–6 The existence of CKD can affect outcomes and reduce survival. In particular, among patients who developed end-stage renal disease (ESRD) and required dialysis, mortality rates were very high.5 It is important for nephrologists who treat transplant survivors to be aware of these complications so as to determine the optimal management of patients with CKD after HSCT.

Here, we report 4 cases of CKD after HSCT. All of them showed pathological renal thrombotic microangiopathy (TMA), and chronic graft-versus-host disease (GVHD) was clinically suspected as the cause of CKD. However, it is generally recognized that the kidney is rarely a target organ of GVHD.

CASE PRESENTATION

A clinical summary of our cases is shown in Table 1 and Figure 1. All patients underwent total body irradiation as a conditioning regimen and were administered calcineurin inhibitors (CNIs) for GVHD prophylaxis. Chimerism analysis of all our cases after HSCT detected more than 90% donor cells, and disease remission was sustained. Because of renal impairment and urinary abnormalities, renal biopsy was performed. Histopathological findings of all cases showed a very similar pattern in the glomeruli and small arterioles. Figure 2 shows representative images of case 3. Typical glomerular features were severe endothelial cell injury characterized by diffuse and globally enlarged subendothelial space, double contour of the glomerular basement membrane (GBM), mesangiolysis, and postmesangiolytic proliferative or postmesangiolytic sclerotic lesions. Global collapse of the glomerular capillaries and severe hyalinosis of the small arteries were occasionally seen (Figure 2a and b). Electron microscopy also showed persistent injury of the glomerular and peritubular capillaries (PTC) of the endothelial cells (Figure 2c). Furthermore, C4d deposition was evident in diffuse glomerular capillaries and was patchy on PTC (Figure 2d).

Case 1

A 49-year-old man presented with proteinuria and renal insufficiency. Renal biopsy was therefore performed. Two years previously, the patient had received an ABO-incompatible umbilical cord blood transplantation (UCBT). His course following UCBT was complicated by grade II acute and extensive chronic GVHD. He received low-dose tacrolimus for skin GVHD at that time. Renal biopsy results showed severe vascular endothelial cell injury. After the biopsy, we recommended a reduction in the tacrolimus dosage because we thought that the cause of endothelial cell injury was CNI nephrotoxicity. Unexpectedly, renal dysfunction became evident as the dosage of tacrolimus was decreased (Figure 1a). Renal impairment progressed when tacrolimus was stopped. Ultimately, the patient required dialysis.
Two years previously, allogeneic bone marrow transplantation (BMT) was used to treat aplastic anemia. He did not develop acute or chronic GVHD; however, he did develop progressive renal insufficiency. When prednisolone and CNI for GVHD prophylaxis were discontinued, renal impairment became evident (Figure 1c). Based on the lessons learned from case 1, we first suspected chronic renal GVHD as the cause of renal insufficiency. Restarting low-dose prednisolone gradually ameliorated the patient’s renal function.

Case 4
A 28-year-old man received an ABO-incompatible UCBT. Systemic TA-TMA–associated CNI toxicity occurred during an early phase after transplantation because the blood concentration of tacrolimus was very high. Acute kidney injury (AKI) developed afterward (Figure 1d). Temporary initiation of hemodialysis and discontinuation of CNI gradually improved the patient’s physical findings and clinical parameters. However, mild renal dysfunction persisted after AKI. When prednisolone for GVHD treatment was decreased, renal impairment gradually progressed. When prednisolone was temporarily increased, a slight improvement in renal function was noted. However, the patient had a fungal infection, and prednisolone was tapered and stopped. Thereafter, his renal function gradually worsened.

DISCUSSION
In this case series, we have described 4 patients with chronic renal insufficiency after allogeneic HSCT. The pathological features of our cases were persistent microvascular endothelial injury in the glomeruli, PTC, and small arterioles of the kidney that were pathologic renal TMA exactly. TA-TMA is a major complication after HSCT. It is assumed that TA-TMA resulting from microvascular endothelial injury is caused mainly by the use of CNI and/or irradiation. When TA-TMA occurs, physicians commonly reduce or discontinue CNI. Two of our case patients promptly developed TA-TMA associated CNI toxicity during an early phase after transplantation. Immediately stopping CNI improved clinical findings. In contrast, late-onset chronic renal insufficiency was improved with the use of prednisolone despite severe renal endothelial injury on kidney biopsy. Changsirikulchai et al. reported an association between renal TMA and acute GVHD.7 They mentioned that stopping or decreasing the dose of CNI might not be helpful for managing TMA. Previously, we described cases of pathological renal TMA associated with chronic GVHD.8,9 We hypothesized that the renal vascular endothelium is a target of
GVHD. Furthermore, using a rat allogeneic BMT model, we determined that the kidney was a target organ of acute GVHD. Recently, Ishida et al. showed a renal-limited TMA case with urinary abnormality while reducing the CNI dosage after transplantation. Renal biopsy results showed pathological renal TMA with C4d deposition in glomerular capillaries and patchy PTCs. These findings suggest that their case was affected by chronic renal GVHD. In our case series, the patient in case 3 clinically presented within renal-limited involvement and findings similar to that of the Ishida et al. case. However, their case differed from ours in that they did not attempt a treatment for renal-limited GVHD.

Regarding irradiation involvement, a recent study also suggested that the use of high-dose TBI was a risk factor for CKD. All our cases received TBI. However, we considered that the exposure to TBI had a low potential for causing renal TMA, because administration of prednisolone ameliorated renal insufficiency in our case patients.

The typical target organs of GVHD include the gastrointestinal tract, liver, skin, eyes, and lungs. However, the kidney is considered an unlikely candidate for GVHD. Several cases of nephrotic syndrome have been reported as renal GVHD. Most of these cases showed membranous nephropathy with subendothelial deposits on biopsy results. It has been suggested that the pathogenesis of membranous nephropathy is related to antigen–antibody complexes. In our cases, C4d deposition was observed on diffuse glomerular capillaries and patchy PTCs. C4d staining is a marker of classic complement activation and is a reliable marker of chronic humoral rejection in kidney transplantation. However, it is not an absolute marker because of the accommodation by the endothelial tissue that becomes resistant to the effects of the complement. Moreover, positive C4d staining for GBM alone has lower reliability due to the possibility of GBM remodeling. Hingorani et al. showed that urinary cytokines might be a useful marker of CKD after HSCT, especially for renal GVHD. They speculated that pro-inflammatory cytokines in the urine are a reflection of the inflammatory milieu of GVHD in the kidney. However, the relationship between kidney injury and GVHD remains controversial. Further studies involving more patients with CKD after HSCT are needed to clarify this relationship.

All our patients showed pathological renal TMA and were clinically suspected of having chronic GVHD. It has been indicated that renal vascular endothelium
may be a target of GVHD. This means that renal GVHD leads to renal endothelial injury and TMA. Persistent renal vascular damage caused by renal GVHD contributes to the progression of CKD. When nephrologists encounter CKD after HSCT in patients with renal TMA, they should be aware of the possibility of GVHD and should consider an increased dose of immunosuppressive drugs.

**DISCLOSURE**

All the authors declared no competing interests.

**REFERENCES**

1. Singh N, Mcneely J, Parikh S, et al. Kidney complications of hematopoietic stem cell transplantation. *Am J Kidney Dis*. 2013;61:809–821.

2. Hingorani S. Renal complications of hematopoietic-cell transplantation. *N Engl J Med*. 2016;374:2256–2267.

3. Hingorani S, Guthrie KA, Schoch G, et al. Chronic kidney disease in long-term survivors of hematopoietic cell transplant. *Bone Marrow Transplant*. 2007;39:223–229.

4. Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. *Cancer*. 2008;113:1580–1587.

5. Cohen EP, Pais P, Moulder JE. Chronic kidney disease after hematopoietic stem cell transplantation. *Semin Nephrol*. 2010;30:627–634.

6. Sakellari I, Barbouti A, Bamichas G, et al. GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation. *Bone Marrow Transplant*. 2013;48:1329–1334.

7. Changsirikulchai S, Myerson D, Guthrie KA, et al. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. *Clin J Am Soc Nephrol*. 2009;4:345–353.

8. Mii A, Shimizu A, Kaneko T, et al. Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Pathol Int*. 2011;61:518–527.
9. Mii A, Shimizu A, Masuda Y, et al. Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hematopoietic stem cell transplantation. *Pathol Int*. 2011;61:34–41.

10. Higo S, Shimizu A, Masuda Y, et al. Acute graft-versus-host disease of the kidney in allogeneic rat bone marrow transplantation. *PLoS One*. 2014;9:e115399.

11. Ishida R, Shimizu A, Kitani T, et al. Hematopoietic stem cell transplantation nephropathy associated with chronic graft-versus-host disease without extrarenal involvement. *Intern Med*. 2016;55:2837–2842.

12. Glezerman IG, Devlin S, Maloy M, et al. Long term renal survival in patients undergoing T-cell depleted versus conventional hematopoietic stem cell transplants. *Bone Marrow Transplant*. 2017;52:733–738.

13. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. *Biol Blood Marrow Transplant*. 2005;11:945–956.

14. Beyar-Katz O, Davila EK, Zuckerman T, et al. Adult nephrotic syndrome after hematopoietic stem cell transplantation: renal pathology is the best predictor of response to therapy. *Biol Blood Marrow Transplant*. 2016;22:975–981.

15. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. *J Am Soc Nephrol*. 2007;18:1046–1056.

16. Gasim AH, Chua JS, Wolterbeek R, et al. Glomerular C4d deposits can mark structural capillary wall remodelling in thrombotic microangiopathy and transplant glomerulopathy: C4d beyond active antibody-mediated injury: a retrospective study. *Transpl Int*. 2017;30:519–532.

17. Hingorani S, Gooley T, Pao E, Sandmaier B, McDonald G. Urinary cytokines after HCT: evidence for renal inflammation in the pathogenesis of proteinuria and kidney disease. *Bone Marrow Transplant*. 2014;49:403–409.